BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Inluriyo (Imlunestrant) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Inluriyo (Imlunestrant)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07918859-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Inluriyo (Imlunestrant): Phase 1 readout est. (NCT07918859)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 1.\nStudy: A Study of Imlunestr
 ant (LY3484356) in Healthy Female Participants\nEstimated primary completi
 on: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imlu
 nestrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07918859
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05514054-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Inluriyo (Imlunestrant): Phase 3 readout est. (NCT05514054)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 3\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant Versus Standard Endocrine Therapy in Participants With
  Early Breast Cancer\nEstimated primary completion: October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05514054
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905001-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Inluriyo (Imlunestrant): Phase 1 readout est. (NCT07905001)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 1\, HR+/HER2- Metastatic Breast
  Cancer.\nStudy: A Phase 1/1b Study of PRT13722 in Participants With Advan
 ced HR+/HER2- Breast Cancer\nEstimated primary completion: 31 October 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07905001
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07832227-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07832227)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2.\nStudy: Imlunestrant/Abemaci
 clib/Selinexor in Ovarian and Endometrial\nEstimated primary completion: 1
  December 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imlun
 estrant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07832227
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07287098-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07287098)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: A St
 udy of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Recep
 tor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2
 -) Early Breast Cancer\nEstimated primary completion: January 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07287098
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410559-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07410559)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: Neoa
 djuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After
  2 Weeks for ER-Positive HER2-Negative Breast Cancer\nEstimated primary co
 mpletion: 1 April 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/imlunestrant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07410559
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07191717-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Inluriyo (Imlunestrant): Phase 2 readout est. (NCT07191717)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 2\, Breast Cancer.\nStudy: Imlu
 nestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive B
 reast Cancer in Patients With Minimal Residual Disease\, MIRI Trial\nEstim
 ated primary completion: 30 April 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/imlunestrant#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07191717
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-9192@assetmemo.bio
DTSTAMP:20261121T004035Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Inluriyo (Imlunestrant): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Inluriyo (Imlunestrant)\, phase 1/2\, HR+/HER2- Metastatic Brea
 st Cancer.\nStudy: First-in-Human Study of Tersolisib (STX-478) as Monothe
 rapy and in Combination With Other Antineoplastic Agents in Participants W
 ith Advanced Solid Tumors\nEstimated primary completion: July 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/imlunestrant#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/imlunestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
